Albutrepenonacog Alfa

證據等級: L5

預測適應症: 6 個

Albutrepenonacog Alfa: Preliminary Assessment — No New Indications Predicted

One-Sentence Summary

Albutrepenonacog alfa (DB13884) is a recombinant coagulation factor IX–albumin fusion protein, known internationally under the brand name Idelvion, used for the treatment and prophylaxis of Hemophilia B. The TxGNN model has not generated any predicted new indications for this drug, and the evidence pack contains significant data gaps that prevent a full evaluation.

Quick Overview

Item	Content
Original Indication	Not recorded in evidence pack (known: Hemophilia B)
Predicted New Indication	None — no TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions, no supporting studies)
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

There are currently no TxGNN predictions for albutrepenonacog alfa, so no mechanistic plausibility assessment can be performed.

Based on publicly available information, albutrepenonacog alfa is a recombinant fusion protein that links human coagulation factor IX (FIX) with recombinant human albumin. The albumin moiety extends the half-life of FIX, allowing less frequent dosing. It restores the missing clotting factor in patients with Hemophilia B (congenital factor IX deficiency), enabling normal haemostasis.

Detailed mechanism of action data was not available in the evidence pack (flagged as Data Gap DG002). Without a TxGNN prediction or MOA data in the pack, no drug repurposing hypothesis can be evaluated at this time.

Clinical Trial Evidence

Currently no related clinical trials registered for any predicted new indication (no new indication was predicted by TxGNN).

Literature Evidence

Currently no related literature available for any predicted new indication.

Taiwan Market Information

Albutrepenonacog alfa has no marketing authorizations recorded with TFDA. The drug is classified as not marketed in Taiwan.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug–drug interactions) returned as data gaps. The TFDA package insert query returned 1 result — this document should be retrieved and parsed to complete the safety profile (see Data Gap DG001).

Data Gaps Requiring Resolution

The following critical data gaps were identified and must be addressed before any repurposing evaluation can proceed:

Gap ID	Item	Severity	Impact	Recommended Remediation
DG001	TFDA Package Insert Warnings/Contraindications	Blocking	Cannot enter S1 safety preliminary assessment	Download and parse package insert PDF from TFDA website
DG002	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API for full MOA data

Conclusion and Next Steps

Decision: Hold

Rationale: No new indications have been predicted by TxGNN for albutrepenonacog alfa. Additionally, the evidence pack contains blocking data gaps (TFDA package insert warnings) and high-severity gaps (MOA data) that preclude any meaningful repurposing assessment. The drug is not marketed in Taiwan, further limiting immediate applicability.

To proceed, the following is needed:

TxGNN model predictions for this drug (currently the predicted_indications array is empty)
Resolution of DG001: Retrieve and parse the TFDA package insert to extract warnings and contraindications
Resolution of DG002: Query DrugBank API for detailed mechanism of action
Confirmation of original approved indication(s) from regulatory source documents
If the drug is not in the TxGNN knowledge graph, assess whether the molecular entity (recombinant FIX–albumin fusion) has sufficient representation in the training data to generate reliable predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.